Research & Development

Rethinking iPSC development
Wednesday, September 10, 2025
A robust CMC strategy cannot be retrofitted; it should guide decisions from the very beginning. For developers aiming to bring iPSC-based therapies to the commercial ... read more
Are LNPs the new AAV?
Wednesday, August 27, 2025
The emergence of nonviral vectors represents an opportunity to propel in vivo gene therapy further into commercial adoption and expand its impact globally. LNPs are ... read more
Navigating the realities of CAR-T cell oncology trials
Wednesday, August 20, 2025
Given the undeniably novel aspect of this new paradigm, however, conducting CAR-T clinical trials presents a unique set of obstacles for sponsors, sites and regulators to... read more
From bispecifics and ADCs to better reagents
Wednesday, April 30, 2025
Advances have allowed for the creation of bispecific, ‘Fc-silenced,’ and other specialized antibody reagents tailored to specific research needs. These engineered ... read more
Unlocking cell therapy’s potential
Friday, November 22, 2024
By continuing to crack the code of complex manufacturing, we can move closer to making long-lasting treatments affordable and available to all read more

Legend opens new cell therapy R&D facility in Philly
The 31,000-square-foot facility is now fully operational and will support Legend’s expanding pipeline of next-generation cell therapies.
Thursday, November 13, 2025
Orbital unveils preclinical in vivo CAR-T data for autoimmune disease
OTX-201 achieved full B cell depletion in blood, spleen, and lymph nodes in a non-human primate study.
Wednesday, July 23, 2025
Vertex shares updated data for islet cell therapy in diabetes
All patients who received a full dose of zimislecel achieved ADA-recommended target HbA1c levels and 10/12 patients were insulin free.
Monday, June 23, 2025